Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

Completed

Conditions: Colorectal Cancer
Neoplasm of Uncertain Malignant Potential

Interventions: Genetic: DNA methylation analysis
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Genetic: reverse transcriptase-polymerase chain reaction
Other: diagnostic laboratory biomarker analysis
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Procedure: biopsy
Procedure: therapeutic conventional surgery
Radiation: fludeoxyglucose F 18

First Posted Date: 2007-10-30

Last Posted Date: 2015-12-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT00550628

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cognitive Changes Associated With Breast Cancer Treatment

Completed

Conditions: Cognitive Side Effects of Cancer Treatments
Stage I, II and III A Breast Cancer
Breast Cancer

Interventions: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence

First Posted Date: 2007-10-29

Last Posted Date: 2021-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 53

Registration Number: NCT00550134

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Biological: rituximab
Biological: sargramostim
Drug: cyclophosphamide
Drug: mitoxantrone hydrochloride
Drug: pentostatin
Genetic: fluorescence in situ hybridization
Genetic: gene rearrangement analysis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Other: flow cytometry
Procedure: biopsy

First Posted Date: 2007-10-18

Last Posted Date: 2016-05-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 50

Registration Number: NCT00546377

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: pentostatin

First Posted Date: 2007-10-08

Last Posted Date: 2017-08-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT00541034

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Liver Cancer
Hepatocellular Carcinoma
Hepatoma

Interventions: Device: Bead Block microspheres
Other: Bead + Dox Arm

First Posted Date: 2007-10-04

Last Posted Date: 2023-08-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 101

Registration Number: NCT00539643

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: oxaliplatin
Genetic: protein expression analysis
Genetic: proteomic profiling
Other: diagnostic laboratory biomarker analysis
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery

First Posted Date: 2007-09-28

Last Posted Date: 2017-03-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT00536874

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure

Completed

Conditions: Psychosocial Effects of Cancer and Its Treatment
Head and Neck Cancer

Interventions: Other: questionnaire administration
Procedure: assessment of therapy complications
Procedure: psychosocial assessment and care
Procedure: quality-of-life assessment

First Posted Date: 2007-09-17

Last Posted Date: 2021-12-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1745

Registration Number: NCT00530049

Locations: 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸
New School for Social Research, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: arsenic trioxide
Drug: idarubicin
Drug: tretinoin

First Posted Date: 2007-09-12

Last Posted Date: 2016-01-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT00528450

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Biological: natural killer cell therapy
Drug: cyclophosphamide
Drug: fludarabine

First Posted Date: 2007-09-10

Last Posted Date: 2016-02-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT00526292

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Phase 2

Terminated

Conditions: Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: sorafenib tosylate
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2007-08-29

Last Posted Date: 2016-02-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT00522301

Locations: 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States

Home Terms & Conditions Privacy Policy